isoxicam and Pain

Within the context of a double blind randomized controlled parallel trial of 2 nonsteroidal antiinflammatory drugs, we validated WOMAC, a new multidimensional, self-administered health status instrument for patients with osteoarthritis of the hip or knee. The pain, stiffness and physical function subscales fulfil conventional criteria for face, content and construct validity, reliability, responsiveness and relative efficiency. WOMAC is a disease-specific purpose built high performance instrument for evaluative research in osteoarthritis clinical trials.

Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Consumer Behavior; Double-Blind Method; Evaluation Studies as Topic; Female; Health Status Indicators; Health Surveys; Hip Joint; Humans; Knee Joint; Male; Middle Aged; Osteoarthritis; Pain; Piroxicam; Random Allocation

Thirteen patients with osteo-arthritis entered a 12-month open-label assessment of the efficacy and safety of a single morning dose of isoxicam 200 mg. Pain scale scores were significantly reduced and this was accompanied by improvement in most of the symptoms. No patients suffered adverse reactions considered to be definitely related to the use of isoxicam and only 3 patients reported adverse reactions (mild weight gain, stomatitis, constipation) probably related to treatment. Isoxicam 200 mg once a day was effective and well tolerated in the long-term symptomatic treatment of osteo-arthritis.

Topics: Aged; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Osteoarthritis; Pain; Piroxicam; Thiazines; Time Factors

A new nonsteroidal anti-inflammatory drug, isoxicam (Maxicam), was studied in patients with degenerative joint disease of the knee or hip. During a six-week, double-blind, placebo-controlled phase involving 176 patients, isoxicam at a dosage of 200 mg once daily was significantly superior to placebo in parameters (knee) of night pain, pain on walking, starting pain, pain on motion, swelling, tenderness, maximal extension, maximal flexion, and limitation of range of motion, and in the parameter (hip) of pain on walking. In patients with knee involvement and those with hip involvement, isoxicam was superior to placebo in overall and global assessments of its efficacy by physicians and patients. When 165 patients continued in a long-term, open-label phase and received isoxicam, a further alleviation of symptoms was noted in those patients who had received isoxicam in the double-blind phase, and a marked and sustained improvement was seen in patients who had received placebo in the double-blind phase.

Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Female; Hip Joint; Humans; Joint Diseases; Knee Joint; Male; Middle Aged; Pain; Piroxicam; Thiazines